Single TearCare treatment significantly improves DED symptoms
Patients treated with a single treatment of TearCare demonstrated significant improvement in dry eye disease (DED) symptom relief after 1 month, according to a study. Those with more severe gland dysfunction treated with TearCare experienced significantly better improving quality of vision and overall DED symptom frequency than those treated with Lipiflow.
A total of 235 patients with symptoms of DED associated with MGD were included in this multicenter, masked, randomized-controlled trial. A single TearCare treatment or LipiFlow treatment was administered in 115 patients and 120 patients, respectively. DED symptoms were assessed using the Ocular Surface Disease Index (OSDI), Symptom Assessment in Dry Eye (SANDE), and Eye Dryness (ED) questionnaires at baseline and at 1 month
Over the study period, total OSDI, SANDE, and ED scores were improved in the TearCare system group. Patients who had more severe disease (MGSS <7) achieved a statistically greater reduction in total OSDI score, OSDI Section B score for quality of vision, and SANDE frequency score with TearCare compared to LipiFlow.
Reference
Holland EJ, Loh J, Bloomenstein M, et al. A Comparison of TearCare and Lipiflow Systems in Reducing Dry Eye Disease Symptoms Associated with Meibomian Gland Disease. Clin Ophthalmol. 2022;16:2861-2871. doi: 10.2147/OPTH.S368319. PMID: 36065356; PMCID: PMC9440678.
